ABSTRACT OBJECTIVES The aim of this paper is to describe the feasibility of a novel transcatheter approach for mitral valve replacement using only venous access.
of stay of 2 to 3 weeks; thus, innovative ways to care for these patients are urgently needed (5, 8) .
Transapical access, an approach familiar to heart teams well versed in transcatheter aortic valve replacement, has been used for mitral valve in valvein-ring implantation but is associated with major complications including bleeding in more than onefourth of patients, and a minimum of 1-week length of hospital stay remains the rule (9) (10) (11) . We, and others, have performed transvenous, transseptal mitral valve replacement with use of an apical rail via a small, percutaneously placed sheath in the ventricular apex or a venous-arterial loop exteriorized at the femoral artery (12) (13) (14) . However, even with closure devices, percutaneous transapical access is associated with risk of hemothorax (15) . Isolated case reports and small series describe mitral valve-in-valve or valve-in-ring procedures via a transseptal route (13, 16) .
To overcome these challenges, simplify access for transcatheter delivery, minimize procedural risk, and accelerate patient recovery, we developed a novel technique of valve-in-valve or valve-in-ring implantation that requires only venous access. We present a case series of patients at high risk of reopera- Coylewright et al. in both of the repairs ( Table 2 ).
The mechanism of prosthetic dysfunction was mitral stenosis in the majority of patients (n ¼ 3) with with an apical rail (14) . We present a case series of This is particularly important with rings, in which the landing zone is shorter and precise placement more challenging. Two patients had had mitral valve repair with an Alfieri stitch. We did not select which orifice to cannulate, and the stitch yielded easily in both cases.
STUDY LIMITATIONS. This is a novel case series of transvenous mitral VIV implantation in 4 patients.
While the technique herein has the potential to limit procedural morbidity, further study is needed in a larger patient cohort. This case series was limited to mitral bioprosthesis and repairs with complete rings. Transseptal Mitral Valve Replacement
CONCLUSIONS

